More STI tests conducted by Sexual Health Centres In 2021, more people visited a Sexual Health Centre (SHC) to get tested for sexually transmitted infections (STIs) than in 2020. This figure is still lower than in 2019, the year before the coronavirus outbreak.
RIVM expands HPV vaccination programme: girls and boys protected from six types of cancer with one vaccine Now not only girls, but also boys will have the opportunity to protect themselves from cancer caused by HPV.
State Secretary Blokhuis: boys will also be vaccinated against HPV virus The vaccine against the HPV human papillomavirus virus will also become available for boys.
Biosafety and Biosecurity on the Global Health Security Agenda Since 2018, the Netherlands leads the way in the field of "Biosafety and Biosecurity" within the international Global Health Security Agenda (GHSA).
Global Infectious Disease Control hampered by the CBD Nagoya Protocol So far, none of the models used by international networks of biobanks to arrange the legal responsibility under the CBD-Nagoya protocol works efficiently.
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Vaccination rate again drops slightly, HPV vaccination rate drops considerably The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.
More gonorrhoea, syphilis and chlamydia at Dutch STI clinics An increasing number of clients tested at a Dutch STI clinic for a sexually transmitted infection (STI) is diagnosed with gonorrhoea, syphilis and chlamydia.
The number of STI tests keeps increasing The number of clients tested for sexually transmitted infections (STIs) at Dutch STI clinics has increased since 2004.
RIVM participates in large EU project to head up global fight against infectious diseases COMPARE, a large EU project intends to speed up the detection of, and response to disease outbreaks among humans and animals worldwide, through the use of new genome technology.